BIOPORTO A/S B DK 1
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neu… Read more
BIOPORTO A/S B DK 1 (2P4) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BIOPORTO A/S B DK 1 (2P4) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIOPORTO A/S B DK 1 - Net Assets Trend (None–None)
This chart illustrates how BIOPORTO A/S B DK 1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIOPORTO A/S B DK 1 (None–None)
The table below shows the annual net assets of BIOPORTO A/S B DK 1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIOPORTO A/S B DK 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIOPORTO A/S B DK 1 Competitors by Market Cap
The table below lists competitors of BIOPORTO A/S B DK 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EMERALD HLDG INC. DL-01
F:EM7
|
$48.72 Million |
|
LightInTheBox Holding Co Ltd ARD
NYSE:LITB
|
$48.72 Million |
|
Gelecek Varlik Yonetimi AS
IS:GLCVY
|
$48.73 Million |
|
GODAVARIB
NSE:GODAVARIB
|
$48.73 Million |
|
Transat A.T. Inc
PINK:TRZBF
|
$48.69 Million |
|
Thor Medical ASA
OL:TRMED
|
$48.68 Million |
|
Ilshinstone
KO:007110
|
$48.68 Million |
|
ASG Corp
VN:ASG
|
$48.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOPORTO A/S B DK 1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIOPORTO A/S B DK 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOPORTO A/S B DK 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIOPORTO A/S B DK 1's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $10,792,710,184
- Average return on equity (ROE) among peers: -33.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOPORTO A/S B DK 1 (2P4) | €- | N/A | N/A | $48.70 Million |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |